U.S. FDA Grants Interchangeable Designation to Fresenius Kabi’s Stelara Biosimilar
The U.S. Food and Drug Administration (FDA) has designated Fresenius Kabi and Formycon AG’s Otulfi (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara (ustekinumab).